PREFERENCES OF PEOPLE LIVING WITH HIV FOR INJECTABLE VERSUS ORAL ANTIRETROVIRAL THERAPY (ART) IN CHINA: A DISCRETE CHOICE EXPERIMENT (DCE...
Author(s)
Christina Donatti, PhD1, EUGENA STAMULI, BSc, MSc2, Mickael HENRY, MSc3, Ana Maria Rodriguez-Leboeuf, BSc, MSc, PhD4, Chadakan Yan, M.D., MBA, PhD5, Melanie Schroeder, BSc, MASc6.
1ViiV Healthcare, TWICKENHAM, United Kingdom, 2IQVIA HELLAS S.A., Athens, Greece, 3IQVIA, Paris, France, 4IQVIA, Madrid, Spain, 5Medical Affairs, GlaxoSmithKline, Bangkok, Thailand, 6ViiV Healthcare, London, United Kingdom.
1ViiV Healthcare, TWICKENHAM, United Kingdom, 2IQVIA HELLAS S.A., Athens, Greece, 3IQVIA, Paris, France, 4IQVIA, Madrid, Spain, 5Medical Affairs, GlaxoSmithKline, Bangkok, Thailand, 6ViiV Healthcare, London, United Kingdom.
OBJECTIVES: ART advancements have expanded options for people living with HIV. This study evaluated preferences of people living with HIV in China for attributes of oral and long-acting injectable (LAI) ART.
METHODS: In a two-step DCE-based survey, adults living with HIV receiving ART evaluated hypothetical ART profiles, including administration mode/frequency/setting, injection-related side effects (SEs), and general SE probability. Participants first chose between two LAI and one oral ART profiles; if oral was selected, a subsequent choice between the two LAI profiles followed. Oral treatments varied by general SE probability and frequency (daily/weekly). Respondents were recruited via online panels and provider referrals. Using a fractional factorial design, 16 choice-tasks were generated. Preference weights were estimated using a random parameter logit-model, and conditional relative importance scores quantified attribute influence on choices.
RESULTS: Among 150 respondents (male: 74.0%; heterosexual: 93.3%; Han: 81.3%), LAI was chosen in 94.0%, 96.7%, and 97.2% of matched profiles when the oral comparator had 0%, 5%, or 10% SE probability. For step one, general SE and administration mode accounted for ~66% of decision-making. Strong preferences included: subcutaneous injections (β=0.949, P<0.0001); 6-month injection-interval (β=0.562, P<0.0001); mild injection site pain (β=0.375, P<0.0001); skin colour changes and/or swelling (coin-sized) lasting 1-3 days (β=0.138, P=0.0066); nodules with 20% chance but lasting only 2-4 weeks (β=0.266, P<0.0001) or 2-3 months (β=0.257, P<0.0001); and 0% SE probability (β=1.005, P<0.0001). Dispreferences (β<0; P<0.05) included: oral therapies; injections every 2 or 4 months; moderate/severe injection pain; skin colour changes and/or swelling (credit-card sized) lasting ≤10 days; 50% nodule probability lasting 2-3 or 6 months; and general SE risk ≥5%. No significant preference for administration setting was observed.
CONCLUSIONS: People living with HIV in China preferred LAI over oral ART, driven by minimising SE and longer dosing intervals. These preferences can inform regulatory decisions and shared decision‑making.
METHODS: In a two-step DCE-based survey, adults living with HIV receiving ART evaluated hypothetical ART profiles, including administration mode/frequency/setting, injection-related side effects (SEs), and general SE probability. Participants first chose between two LAI and one oral ART profiles; if oral was selected, a subsequent choice between the two LAI profiles followed. Oral treatments varied by general SE probability and frequency (daily/weekly). Respondents were recruited via online panels and provider referrals. Using a fractional factorial design, 16 choice-tasks were generated. Preference weights were estimated using a random parameter logit-model, and conditional relative importance scores quantified attribute influence on choices.
RESULTS: Among 150 respondents (male: 74.0%; heterosexual: 93.3%; Han: 81.3%), LAI was chosen in 94.0%, 96.7%, and 97.2% of matched profiles when the oral comparator had 0%, 5%, or 10% SE probability. For step one, general SE and administration mode accounted for ~66% of decision-making. Strong preferences included: subcutaneous injections (β=0.949, P<0.0001); 6-month injection-interval (β=0.562, P<0.0001); mild injection site pain (β=0.375, P<0.0001); skin colour changes and/or swelling (coin-sized) lasting 1-3 days (β=0.138, P=0.0066); nodules with 20% chance but lasting only 2-4 weeks (β=0.266, P<0.0001) or 2-3 months (β=0.257, P<0.0001); and 0% SE probability (β=1.005, P<0.0001). Dispreferences (β<0; P<0.05) included: oral therapies; injections every 2 or 4 months; moderate/severe injection pain; skin colour changes and/or swelling (credit-card sized) lasting ≤10 days; 50% nodule probability lasting 2-3 or 6 months; and general SE risk ≥5%. No significant preference for administration setting was observed.
CONCLUSIONS: People living with HIV in China preferred LAI over oral ART, driven by minimising SE and longer dosing intervals. These preferences can inform regulatory decisions and shared decision‑making.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
PCR21
Topic
Patient-Centered Research
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Reproductive & Sexual Health